Summary
Other Scenarios:
- BRL - JNJ
- BRL - GSK
- JNJ - NRPH
- GSK - NRPH
| Buyer: | Barr Pharmaceuticals, Inc. (BRL) | Last Price: | 46.70 | Market Cap.: | 4.98B |
|---|---|---|---|---|---|
| Target: | New River Pharmaceuticals, Inc. (NRPH) | Last Price: | 63.73 | Market Cap.: | 2.36B |
Lines of Business Summary:
- Barr Pharmaceuticals, Inc. (BRL) competes in 1 industry and 223 product/service groups
- New River Pharmaceuticals, Inc. (NRPH) competes in 1 industry and 4 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- Barr Pharmaceuticals, Inc. (BRL) has 4 and New River Pharmaceuticals, Inc. (NRPH) has 0 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
*Healthcare |
|
|
867 |
Biopharmaceuticals |
|
|
330 |
Medical Devices |
|
244 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 153)
|
Target (Total: 5)
|
Buyer
|
Targetn/a |
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 3)
|
Target (Total: 1)
|
Buyer (Total: 7)
|
Target (Total: 0)n/a |
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 8,500 | 38 |
| Revenue Per Employee | 275,594.1 | 248,982.3 |
| Total Revenue | 584.0 | 2.5 |
| Total Expenses | 912.0 | 50.1 |
Other Revenue
|
47.4 | 0.0 |
Cost of Revenue
|
285.8 | 0.0 |
SG&A Expense
|
178.0 | 29.3 |
Research & Development
|
67.5 | 16.6 |
Other Operating Expense
|
0.0 | 0.0 |
Operating Income
|
-328.0 | -47.7 |
Unusual Income
|
380.7 | 4.3 |
LT Debt to Capital
|
56.94 | -0 |
Fwd P/E
|
15.36 | -77.72 |
Fwd P/Rev
|
2.02 | 27.92 |
| Book Value | 1,465.2 | -109.7 |
Curr Portion of LTD/Cap Lease
|
742.4 | 137.8 |
Individual Company Summary
Focused
Buyer
Focused (
):
*Healthcare > Biopharmaceuticals
Target
Focused (
):
*Healthcare > Biopharmaceuticals > Neurology
Business Description
Buyer
Barr Pharmaceuticals, Inc. is primarily a holding company. The Company's subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceutical products, respectively. It operates in two business segments. In the generic pharmaceutical segment, it manufactures and distributes approximately 150 different dosage forms and strengths of approximately 75 different generic pharmaceutical products, including 22 oral contraceptive products that represent the largest category of its generic product portfolio. In the proprietary pharmaceutical segment, the Company manufactures and distributes 19 proprietary pharmaceutical products, largely concentrated in the women's healthcare therapeutic category. These products include SEASONALE and SEASONIQUE extended-cycle oral contraceptive products, and Cenestin (synthetic conjugated estrogens, A) and ENJUVIA (synthetic conjugated estrogens, B) line of hormone therapy products.
Target
New River Pharmaceuticals Inc. is a specialty pharmaceutical company developing pharmaceuticals. Utilizing the Company's Carrierwave technology, it is developing molecular entities that are derivatives of public domain actives, and attempting to address certain deficiencies associated with drugs on the market. The Company?s drug development pipeline includes three active programs in clinical or preclinical development stages. All of its drug candidates are small molecules designed for oral delivery. Vyvanse is intended to provide a safer, abuse-resistant and effective alternative to existing amphetamine-based therapies used to treat Attention Deficit Hyperactiviy Disorder (ADHD). The Company is developing NRP290 to treat acute pain as an alternative to Lortab, Vicodin and Vicoprofen. NRP290 is intended to provide a safer, abuse-resistant and an effective alternative to opioids.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
Gross Margin %
|
63.56 | 100 |
Operating Margin %
|
0.07 | -174.85 |
Quick Ratio
|
1.25 | 0.88 |
Current Ratio
|
1.72 | 0.89 |
Coverage Ratio
|
-5.91 | -0.06 |
| Total Assets | 4,961.9 | 151.5 |
| Return on Equity % | -12.31 | n/a |
| Return on Assets % | -3.64 | -37.43 |
Cash+ ST Inv. Per Share
|
8.51 | 3.98 |
| Total Debt | 2,679.7 | 137.8 |
| Total Debt to Equity % | 182.88 | 0 |
| Total Debt to Tangible Equity % | n/a | n/a |
Debt to Asset %
|
54.01 | 90.92 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
*Healthcare |
|
|
Biopharmaceuticals |
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
|
|
|
Medical Devices |
|
|
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes medical devices that diagnose and treat female reproductive diseases; devices used to care for women during pregnancy, childbirth, and the post-partum period are also included in this sector.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
*Healthcare |
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Dermatology |
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit the inflammation by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
Ophthalmology |
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation preventingcyclooxygenase activity.
Buyer Products:
|
|
|
Systemic |
|
|
Anaphylactic Shock |
|
|
Adjunctive Treatments |
|
|
Antihistamines/Antiserotonins
Therapeutics that assist the primary treatment of a life-threatening systemic allergic reaction resulting from secondary or subsequent exposure to a foreign substance by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
Upper Respiratory |
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.
Buyer Products:
|
|
|
Cardiovascular System |
|
|
Heart Disorders |
|
|
Angina |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Arrhythmia |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Buyer Products:
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.
Buyer Products:
|
|
|
Heart Failure (HF) |
|
|
Complications |
|
|
Edema |
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
Myocardial Infarction (MI) |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
Vascular Disorders |
|
|
Atherosclerosis |
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat the narrowing or hardening of arteries by inhibiting the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.
Buyer Products:
|
|
|
Hypertension |
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.
Buyer Products:
|
|
|
Peripheral Vascular Disease |
|
|
Blood Viscosity Reducing Agents
Therapeutics that treat arterial obstruction outside of the heart by altering the flow of red blood cells.
Buyer Products:
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat arterial obstruction outside of the heart by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
Thromboembolism |
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
Platelet Aggregation Inhibitors |
|
|
Phosphodiesterase Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing platelets from clumping together.
Buyer Products:
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
Tremors |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that prevent or treat involuntary trembling by blocking the beta adrenergic receptors in muscle tissue.
Buyer Products:
|
|
|
Dermatology |
|
|
Acne |
|
|
Vulgaris |
|
|
Antibacterial Agents |
|
|
Macrolides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.
Buyer Products:
|
|
|
Lesion/Scaling Disorders |
|
|
Chronic Urticaria |
|
|
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.
Buyer Products:
|
|
|
Pruritus |
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
Psoriasis |
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a slow growing, chronic inflammatory skin disorder characterized by dry, scaling patches by inhibiting an enzyme needed for the synthesis of DNA.
Buyer Products:
|
|
|
Immunosuppressants
Therapeutics that treat a slow growing, chronic inflammatory skin disorder characterized by dry, scaling patches by suppressing the immune system.
Buyer Products:
|
|
|
Digestive System |
|
|
Gastrointestinal Tract Disorders |
|
|
Gastroduodenal Disorders |
|
|
Peptic Ulcers |
|
|
Duodenal |
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
Gastric |
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
Gastroesophageal Disorders |
|
|
Acid Indigestion/Heartburn |
|
|
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.
Buyer Products:
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat Gastroesophageal Reflux Disease (GERD) by blocking dopamine receptor and stimulating gastrointestinal movement without stimulating secretions from the pancreas, stomach or gall bladder.
Buyer Products:
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
Gastroparesis |
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat gastroparesis by blocking the action of dopamine.
Buyer Products:
|
|
|
Nausea/Vomiting |
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.
Buyer Products:
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Buyer Products:
|
|
|
Intestinal Disorders |
|
|
Intestinal Intubation |
|
|
Dopamine Receptor Blocking Agents
Therapeutics that cause bowel evacuation prior to intubation by blocking the action of dopamine.
Buyer Products:
|
|
|
Liver Disorders |
|
|
Cirrhosis |
|
|
Complications |
|
|
Edema |
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Buyer Products:
|
|
|
Endocrinology/Metabolism |
|
|
Adrenal Gland Disorders |
|
|
Adrenocortical Insufficiency |
|
|
Synthetic Adrenocortical Steroids
Therapeutics that treat Adrenocortical Insufficiency by acting on the distal tubules
of the kidney to enhance the reabsorption of sodium ions and to increase the urinary excretion of both potassium and hydrogen ions.
Buyer Products:
|
|
|
Diabetes |
|
|
Induced Complications |
|
|
Central Diabetes Insipidus |
|
|
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.
Buyer Products:
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.
Buyer Products:
|
|
|
Biguanides/Insulin Stimulating Agents
Therapeutics that control high blood sugar by stimulating the release of insulin as well as decreasing the production of glucose in the liver.
Buyer Products:
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Buyer Products:
|
|
|
General Hormone Treatments |
|
|
Estrogens
Therapeutics that treat hormonal disorders by providing estrogen.
Buyer Products:
|
|
|
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
Intermediary Metabolism Disorders |
|
|
Gout |
|
|
Gouty Arthritis |
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Buyer Products:
|
|
|
Hyperuricemia |
|
|
Urate Resorption Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys.
Buyer Products:
|
|
|
Hypercholesterolemia |
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat elevated cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
Hyperlipidemia |
|
|
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
Reproductive Disorders |
|
|
Amenorrhea |
|
|
Progestins
Female sex hormone necessary for the development of the female reproductive system.
Buyer Products:
|
|
|
Menopause |
|
|
Estrogens
Therapeutics that are female sex hormones.
Buyer Products:
|
|
|
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.
Buyer Products:
|
|
|
Progestins
Therapeutics that are female sex hormones.
Buyer Products:
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
Hematology |
|
|
Hemophilia |
|
|
Hemophilia A |
|
|
Antidiuretic Agents
Therapeutics that treat prevent the loss of water in the urine.
Buyer Products:
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
Anemia |
|
|
Folic Acid Derivatives
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues caused by folic acid deficiency.
Buyer Products:
|
|
|
Serum Factor Disorders |
|
|
Hypercholesterolemia |
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
Hyperlipidemia |
|
|
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
Hyperuricemia |
|
|
Urate Resorption Inhibitors
Therapeutics that prevents the resorption of urate within the kidneys.
Buyer Products:
|
|
|
Hypokalemia |
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.
Buyer Products:
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
Thrombocythemia |
|
|
Megakaryocyte Maturation Inhibitors
Therapeutics that prevents the maturation of platelet producing cells.
Buyer Products:
|
|
|
Immunology |
|
|
Autoimmune Disorders |
|
|
Arthritis |
|
|
Rheumatoid Arthritis (RA) |
|
|
Analgesics |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.
Buyer Products:
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Buyer Products:
|
|
|
Immunotherapy |
|
|
Immunosuppressants
Therapeutics that treat chronic inflammation of the joints by inhibiting a full immune response.
Buyer Products:
|
|
|
Psoriasis |
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a chronic autoimmune disease characterized by thickened skin with silver scales by blocking the action of the dihydrofolate enzyme.
Buyer Products:
|
|
|
Immunosuppressants
Therapeutics that treat a chronic autoimmune disease characterized by thickened skin with silver scales by inhibiting a full immune response.
Buyer Products:
|
|
|
Immune Deficiency Disorders |
|
|
Hereditary Angioedema |
|
|
Gonadotropin Inhibitors
Therapeutics that treat swelling under the skin caused by the absence of an essential immune regulator by increasing levels of C4 complement component.
Buyer Products:
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
Infectious Diseases |
|
|
Bacterial |
|
|
Antibacterial Agents |
|
|
Broad Spectrum |
|
|
Antibiotics |
|
|
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
Nitroimidazoles
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and causing cell death.
Buyer Products:
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
Narrow Spectrum |
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
Otitis Media |
|
|
Macrolides/Sulfonamides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis and by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
Respiratory System |
|
|
Pneumonia |
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
Respiratory Tract Infections |
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
Tuberculosis |
|
|
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.
Buyer Products:
|
|
|
Systemic |
|
|
Leprosy |
|
|
Erythema Nodosum Leprosum (ENL) |
|
|
Immunomodulatory Agents
Therapeutics that treat a bacterial infection characterized by the formation of tender, red nodules on the front of the legs by stimulating the immune system.
Buyer Products:
|
|
|
Urology |
|
|
Prostatitis |
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
Urinary Tract Infections (UTI) |
|
|
Antibacterial Agents (Antibiotics) |
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
Mycological (Fungal) |
|
|
Antifungal Agents |
|
|
Broad Spectrum |
|
|
Azoles |
|
|
Imidazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Triazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Narrow Spectrum |
|
|
Dermatology |
|
|
Candidiasis |
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the skin caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Buyer Products:
|
|
|
Digestive System |
|
|
Mucous |
|
|
Candidiasis |
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the secretory lining of the tissues caused by a yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Buyer Products:
|
|
|
Nervous System |
|
|
Cryptococcal Meningitis |
|
|
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
Esophageal Candidiasis |
|
|
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Oropharyngeal Candidiasis |
|
|
Azoles |
|
|
Triazoles
Therapeutics that treat fungal infections of the mouth and pahrynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the mucosa caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Buyer Products:
|
|
|
Urology |
|
|
Vaginal Candidiasis |
|
|
Azoles |
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Protozoal |
|
|
Antiprotozoal Agents |
|
|
Broad Spectrum |
|
|
Nitroimidazoles
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Buyer Products:
|
|
|
Narrow Spectrum |
|
|
Malaria |
|
|
Aminoquinolines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by inhibiting parasite growth.
Buyer Products:
|
|
|
Viral |
|
|
RNA Viruses |
|
|
Retrovirus |
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
Musculoskeletal System |
|
|
Skeletal Disorders |
|
|
Bone Disorders |
|
|
Osteoporosis |
|
|
Hormonal Treatments |
|
|
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Buyer Products:
|
|
|
Estrogens/Progestins
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Buyer Products:
|
|
|
Joint Disorders |
|
|
Ankylosing Spondylitis |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
Gouty Arthritis |
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Buyer Products:
|
|
|
Osteoarthritis (OA) |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
Rheumatoid Arthritis (RA) |
|
|
Analgesics |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.
Buyer Products:
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Buyer Products:
|
|
|
Immunotherapy |
|
|
Immunosuppressants
Therapeutics that treat rheumatoid arthritis by suppressing the immune system.
Buyer Products:
|
|
|
Neurology |
|
|
Neurological Disorders |
|
|
Alzheimer`s Disease |
|
|
Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine, and by modulating the receptor that binds nicotine.
Buyer Products:
|
|
|
Epilepsy |
|
|
Partial Seizures |
|
|
Complex |
|
|
Adjunctive Therapy |
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Buyer Products:
|
|
|
Monotherapy |
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Buyer Products:
|
|
|
Simple |
|
|
Adjunctive Therapy |
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
Monotherapy |
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
Primary Generalized Seizures |
|
|
Absence (Petit Mal) |
|
|
Adjunctive Therapy |
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
Monotherapy |
|
|
Calcium Channel Blocking Agents
Therapeutics that treat Petit Mal Seizures by preventing the entrance of calcium into nerve cells.
Buyer Products:
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
Akinetic Pattern |
|
|
Adjunctive Therapy |
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
Monotherapy |
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic
Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
Myoclonic |
|
|
Adjunctive Therapy |
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.
Buyer Products:
|
|
|
Monotherapy |
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
Tonic-Clonic (Grand Mal) |
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
Headaches |
|
|
Tension Type |
|
|
Analgesics/Sedatives/Vasoconstrictive Agents
Therapeutics that treat tension type headaches by inhibiting the action of prostaglandins, constricting blood vessels in the brain thus reducing the pulsing action of blood in the cerebral arteries, and exerting a mild sedative effect.
Buyer Products:
|
|
|
Vascular (Migraine) |
|
|
Acute Treatments |
|
|
Analgesics/Sedatives/Vasoconstrictive Agents
Therapeutics that treat migraine by inhibiting the action of prostaglandins, constricting blood vessels in the brain thus reducing the pulsing action of blood in the cerebral arteries, and exerting a mild sedative effect.
Buyer Products:
|
|
|
Prophylactic Treatments |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat Migraine by inhibiting stimulation of beta adrenergic receptors.
Buyer Products:
|
|
|
Neuromuscular Disorders |
|
|
Myasthenia Gravis (MG) |
|
|
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.
Buyer Products:
|
|
|
Parkinson`s Disease (PD) |
|
|
Adjunctive Treatments |
|
|
Cholinergic Receptor Blocking Agents
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by blocking acetylcholine receptors on neurons.
Buyer Products:
|
|
|
Psychiatric Disorders |
|
|
Anxiety |
|
|
Generalized Anxiety Disorder (GAD) |
|
|
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.
Buyer Products:
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.
Buyer Products:
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
Obsessive Compulsive Disorder (OCD) |
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
Panic Disorder |
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
Post-Traumatic Stress Disorder (PTSD) |
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
Social Anxiety Disorder (SAD) |
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
Childhood/Adolescent Disorders |
|
|
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hyperactivity in children due to an abnormally short attention span.
Buyer Products:
Target Products:
|
|
|
Enuresis (Bedwetting) |
|
|
Antidiuretic Agents
Therapeutics that treat enuresis by suppressing the passing of urine.
Buyer Products:
|
|
|
Eating Disorders |
|
|
Bulimia |
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
Mood Disorders |
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
Lithium-Based Agents
Therapeutics that treat bipolar disorders by decreasing the concentrations of neurotransmitters.
Buyer Products:
|
|
|
Monoaminergic Antagonists
Therapeutics that treat bipolar disorder by blocking the serotonin and dopamine receptors.
Buyer Products:
|
|
|
Depression |
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.
Buyer Products:
|
|
|
Premenstrual Dysphoric Disorders |
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
Schizophrenia |
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.
Buyer Products:
|
|
|
Monoaminergic Antagonists
Therapeutics that treat schizophrenia by blocking the serotonin and dopamine receptors.
Buyer Products:
|
|
|
Sleep Disorders |
|
|
Insomnia |
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
Narcolepsy |
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat narcolepsy by stimulating the adrenergic receptors, which causes nervous system stimulation.
Buyer Products:
|
|
|
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hronic and sudden daytime sleepiness.
Buyer Products:
|
|
|
Obstetrics/Gynecology |
|
|
Child Birth/Pregnancy |
|
|
Prevention (Contraception) |
|
|
Contraceptives (Birth Control) |
|
|
Estrogens
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Buyer Products:
|
|
|
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Buyer Products:
|
|
|
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system
Buyer Products:
|
|
|
Female Genital Disorders |
|
|
Endometriosis |
|
|
Gonadotropin Inhibitors
Therapeutics that treat endometriosis by preventing the release of the pituitary gland hormone, gonadotropin.
Buyer Products:
|
|
|
Ovarian |
|
|
Hypogonadism |
|
|
Hormonal Treatments |
|
|
Estrogens
These are female sex hormones.
Buyer Products:
|
|
|
Vulvovaginal |
|
|
Atrophy |
|
|
Hormonal Treatments |
|
|
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.
Buyer Products:
|
|
|
Estrogens/Progestins
Therapeutics that treat disorders characterized by thinning of the vaginal walls with a combination of the female sex hormones estrogen and progestin.
Buyer Products:
|
|
|
Oncology |
|
|
Breast Cancer |
|
|
Localized |
|
|
Antimetabolite Agents |
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage breast cancers by inhibiting an enzyme needed for the synthesis of DNA.
Buyer Products:
|
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancers by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Buyer Products:
|
|
|
Progestins
Therapeutics that treat and manage breast cancers by providing progestins which in turn results in decreased estrogen levels.
Buyer Products:
|
|
|
Metastatic |
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancer by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Buyer Products:
|
|
|
Dermatology |
|
|
Malignant Melanoma |
|
|
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage cancers of pigment cells in the epidermis and dermis by interfering with DNA synthesis.
Buyer Products:
|
|
|
Digestive System |
|
|
Colon Cancer/Colorectal Cancer |
|
|
Palliative Agents |
|
|
Folic Acid Derivatives
Therapeutics that treat colorectal cancers by helping to reduce toxicity by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.
Buyer Products:
|
|
|
Head/Neck Cancer |
|
|
Localized |
|
|
Antimetabolite Agents |
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by inhibiting the production of DNA.
Buyer Products:
|
|
|
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by interfering with DNA synthesis.
Buyer Products:
|
|
|
Hematology |
|
|
Leukemia (White Blood Cell Cancer) |
|
|
Lymphoid |
|
|
Acute |
|
|
Lymphocytic |
|
|
Antimetabolite Agents |
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of lymphocytic cells by inhibiting an enzyme needed for the synthesis of DNA.
Buyer Products:
|
|
|
Meningeal |
|
|
Antimetabolite Agents |
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage neoplasm's of immature immune cells that have spread to the brain by inhibiting an enzyme needed for the synthesis of DNA.
Buyer Products:
|
|
|
Myeloid |
|
|
Chronic |
|
|
Myelogenous (CML) |
|
|
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by interfering with DNA synthesis.
Buyer Products:
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
Non-Hodgkin`s Lymphoma (NHL) |
|
|
Antimetabolite Agents |
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage lymphomas of B-cells and T-cells by inhibiting the production of DNA.
Buyer Products:
|
|
|
Multiple Myeloma (Plasma Cell Cancer) |
|
|
Immunomodulatory Agents
Therapeutics that treat multiple myeloma by stimulating the immune system.
Buyer Products:
|
|
|
Musculoskeletal System |
|
|
Bone Cancer |
|
|
Osteosarcoma |
|
|
Palliative Agents |
|
|
Folic Acid Derivatives
Therapeutics that are meant to reduce the toxicity of treating malignant tumors of the bone by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.
Buyer Products:
|
|
|
Urology |
|
|
Endometrial Cancer |
|
|
Localized |
|
|
Progestins
Therapeutics that treat and manage cancer of the endometrial cells lining the uterus by providing a female sex hormone necessary for the development of the female reproductive system.
Buyer Products:
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
Metastatic |
|
|
Hormonal Treatments |
|
|
Progestins
Therapeutics that treat and manage renal cancers that have spread beyond their original tumor site by supplying a female sex hormone necessary for the development of the female reproductive system.
Buyer Products:
|
|
|
Ovarian Cancer |
|
|
Adenocarcinoma |
|
|
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage cancer of cells lining the ovary by interfering with DNA synthesis.
Buyer Products:
|
|
|
Prostate Cancer |
|
|
Localized |
|
|
Androgen Receptor Blockers
Therapeutics that treat prostate cancer by blocking androgen receptors. This limits the action of male hormones which have been implicated as a causative agent in prostate cancer.
Buyer Products:
|
|
|
Metastatic |
|
|
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.
Buyer Products:
|
|
|
Ophthalmology |
|
|
Degenerative Disorders |
|
|
Glaucoma |
|
|
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.
Buyer Products:
|
|
|
Irritation/Inflammation |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
Pain Management |
|
|
Anesthesia |
|
|
General (Systemic) |
|
|
Adjunctive |
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
Narcotics |
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
Non-Narcotics |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.
Buyer Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of pain in very early stages of research where no human subject is involved.
Target Products:
|
|
|
Respiratory System |
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
Asthma |
|
|
Prophylactic Treatments |
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Buyer Products:
|
|
|
Bronchitis |
|
|
Prophylactic Treatments |
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Buyer Products:
|
|
|
Emphysema |
|
|
Prophylactic Treatments |
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Buyer Products:
|
|
|
Upper Respiratory Tract Disorders |
|
|
Coughs/Colds |
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
Antitussives
Therapeutics that relieve or prevent coughs.
Buyer Products:
|
|
|
Decongestants/Expectorants/Opioids
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and help in ejection of mucous.
Buyer Products:
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.
Buyer Products:
|
|
|
Surgery |
|
|
Cardiovascular System |
|
|
Thrombosis |
|
|
Thrombin Inhibitors
Therapeutics that thin the blood of a blocked blood vessel during surgery by blocking an enzyme involved in the clotting process.
Buyer Products:
|
|
|
General |
|
|
Complications |
|
|
Nausea/Vomiting |
|
|
Serotonin Receptor Antagonists
Therapeutics that prevent or treat post surgical nausea and vomiting by blocking the receptors that bind serotonin, a neurotransmitter.
Buyer Products:
|
|
|
Musculoskeletal System |
|
|
Deep Vein Thrombosis (DVT) |
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.
Buyer Products:
|
|
|
Ophthalmology |
|
|
Ocular Inflammation |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation resulting from surgical procedures to remove cataracts by preventing cyclooxygenase activity.
Buyer Products:
|
|
|
Toxicology |
|
|
Substance Abuse |
|
|
Withdrawal |
|
|
Alcohol |
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Buyer Products:
|
|
|
Opioid Antagonists
Therapeutics that treat alcohol dependence by blocking the effect of opioids.
Buyer Products:
|
|
|
Narcotics |
|
|
Opioid Antagonists
Therapeutics that treat narcotic addiction by blocking the effect of opioids.
Buyer Products:
|
|
|
Transplantation |
|
|
Heart |
|
|
Rejection Prophylaxis |
|
|
Immunosuppressants
Therapeutics that help manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
|
|
|
Hepatic (Liver) |
|
|
Rejection Prophylaxis |
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
|
|
|
Renal (Kidney) |
|
|
Rejection Prophylaxis |
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
|
|
|
Urology |
|
|
Male Genital Disorders |
|
|
Prostate |
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
5-Alpha Reductase Inhibitors
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT), a substance that causes enlargement of the prostate.
Buyer Products:
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Buyer Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Urological Disorders |
|
|
Bladder |
|
|
Neurogenic Bladder Disease |
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
Cholinergic Agents
Therapeutics that treat bladder dysfunction arising from the malfunction of autonomic nerves that control bladder function with choleinergic agents.
Buyer Products:
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
Anticholinergic Agents
Therapeutics that treat the inability to control urinary excretory functions by blocking the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
Kidney (Renal) |
|
|
Chronic Renal Failure (CRF) |
|
|
Complications |
|
|
Edema |
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Buyer Products:
|
|
|
Weight Management |
|
|
Anorexia (Appetite Loss) |
|
|
Progestins
Therapeutics that treat weight loss and other conditions arising from the uncontrolled loss of appetite by administration of hormone progestins.
Buyer Products:
|
|
|
Cachexia |
|
|
Anabolic Testosterone Analogs
Therapeutics containing a class of compounds that boost the body's metabolism and help in gaining weight.
Buyer Products:
|
|
|
Progestins
Therapeutics that treat cachexia by providing female hormones.
Buyer Products:
|
|
|
Medical Devices |
|
|
General Surgery |
|
|
Invasive |
|
|
Transplantation |
|
|
Organ Preservation
Devices used to preserve organs prior to transplantation.
Buyer Products:
|
|
|
Obstetrics/Gynecology |
|
|
Treatment |
|
|
Procedure Specific |
|
|
Contraception |
|
|
Intrauterine Devices (IUD)
IUDs, or Intrauterine devices, are a form of birth control used by women.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Johnson & Johnson
|
|
n/a | 178,185.093 | 16.12 | 15.74 | 3.34 | 3.00 | 16.76 | |
Novartis AG (ADR)
|
|
n/a | 130,937.348 | 24.87 | 16.90 | 3.56 | 3.30 | 6.59 | |
Eli Lilly & Co.
|
|
n/a | 62,916.207 | 23.63 | 16.66 | 4.01 | 3.60 | 5.73 | |
Shire plc (ADR)
|
|
n/a | 10,722.895 | 38.54 | 30.08 | 5.97 | 4.86 | 11.38 | |
Watson Pharmaceuticals, Inc.
|
|
n/a | 2,734.972 | n/a | 21.87 | 1.38 | 1.07 | 257.36 | |
Noven Pharmaceuticals, Inc.
|
|
n/a | 591.006 | 36.97 | 21.12 | 9.74 | 7.12 | 3.39 | |
| Buyer | |||||||||
Johnson & Johnson
|
|
n/a | 178,185.093 | 16.12 | 15.74 | 3.34 | 3.00 | 16.76 | |
Roche Holding Ltd. (ADR)
|
|
n/a | 157,158.883 | 24.84 | 24.29 | 4.66 | n/a | 6.98 | |
| Target | |||||||||
Johnson & Johnson
|
|
n/a | 178,185.093 | 16.12 | 15.74 | 3.34 | 3.00 | 16.76 | |
GlaxoSmithKline plc (ADR)
|
|
n/a | 161,058.996 | 15.12 | 15.20 | 3.51 | 3.60 | 15.27 | |
Novartis AG (ADR)
|
|
n/a | 130,937.348 | 24.87 | 16.90 | 3.56 | 3.30 | 6.59 | |
Abbott Laboratories
|
|
n/a | 87,986.029 | 51.25 | 20.29 | 3.91 | 3.87 | n/a | |
Tyco International Ltd.
|
|
n/a | 63,567.884 | 16.04 | 16.08 | 1.52 | 1.46 | 11.09 | |
Eli Lilly & Co.
|
|
n/a | 62,916.207 | 23.63 | 16.66 | 4.01 | 3.60 | 5.73 | |
Shire plc (ADR)
|
|
n/a | 10,722.895 | 38.54 | 30.08 | 5.97 | 4.86 | 11.38 | |
Endo Pharmaceuticals
|
|
n/a | 4,079.028 | 29.59 | 18.17 | 4.48 | 3.93 | 5.22 | |
Watson Pharmaceuticals, Inc.
|
|
n/a | 2,734.972 | n/a | 21.87 | 1.38 | 1.07 | 257.36 | |
Ligand Pharmaceuticals Inc.
|
|
n/a | 751.502 | n/a | -37.20 | 5.33 | 27.49 | n/a | |
Noven Pharmaceuticals, Inc.
|
|
n/a | 591.006 | 36.97 | 21.12 | 9.74 | 7.12 | 3.39 | |
Pain Therapeutics, Inc.
|
|
n/a | 356.877 | 57.67 | 161.00 | 6.62 | 5.98 | 4.58 | |
Nastech Pharmaceutical
|
|
n/a | 280.190 | n/a | -8.46 | 9.83 | 9.84 | 6.47 | |
Acura Pharmaceuticals, Inc.
|
|
n/a | 256.652 | n/a | n/a | n/a | n/a | n/a | |
Amarin Corporation plc (ADR)
|
|
n/a | 225.804 | n/a | -8.59 | 448.00 | n/a | 7.82 | |
UCB S.A.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Purdue Pharma L.P.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
Mack-Cali Realty Corp.
|
|
n/a | 3,239.119 | 22.70 | 13.73 | 4.38 | 4.85 | 2.12 | |
Indevus Pharmaceuticals
|
|
n/a | 407.437 | n/a | -8.95 | 7.46 | 6.19 | n/a | |
Common Sense Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
Albany Molecular Research, Inc.
|
|
n/a | 314.068 | 143.99 | 32.03 | 1.75 | 1.63 | 1.12 | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
McKesson Corporation
|
|
27.00% | 17,404.791 | 19.87 | 20.75 | 0.19 | 0.19 | 4.10 | |
Cardinal Health, Inc.
|
|
15.00% | 29,833.986 | 20.19 | 21.92 | 0.35 | 0.34 | 6.61 | |
AmerisourceBergen Corp.
|
|
11.00% | 10,232.923 | 20.77 | 21.02 | 0.16 | 0.16 | 8.24 | |
Walgreen Company
|
|
10.00% | 46,278.291 | 23.55 | 22.34 | 0.91 | 0.86 | 4.38 | |
Warner Chilcott Ltd.
|
|
n/a | 4,036.488 | n/a | 17.51 | 5.35 | 4.85 | n/a | |
Indevus Pharmaceuticals
|
|
n/a | 407.437 | n/a | -8.95 | 7.46 | 6.19 | n/a | |
Government - United States
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Shire plc (ADR)
|
|
n/a | 10,722.895 | 38.54 | 30.08 | 5.97 | 4.86 | 11.38 | |
| Buyer | |||||||||
Abbott Laboratories
|
|
n/a | 87,986.029 | 51.25 | 20.29 | 3.91 | 3.87 | n/a | |
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 22,436.579 | 41.09 | 17.88 | 2.67 | 2.49 | 20.09 | |
Akzo Nobel N.V. (ADR)
|
|
n/a | 22,122.858 | 13.37 | 19.18 | 1.21 | 1.40 | 4.87 | |
Shire plc (ADR)
|
|
n/a | 10,722.895 | 38.54 | 30.08 | 5.97 | 4.86 | 11.38 | |
Cephalon, Inc.
|
|
n/a | 4,983.348 | 34.41 | 20.73 | 2.82 | 2.84 | 101.17 | |
King Pharmaceuticals, Inc.
|
|
n/a | 4,861.564 | 16.82 | 12.34 | 2.44 | 2.44 | 3.69 | |
Warner Chilcott Ltd.
|
|
n/a | 4,036.488 | n/a | 17.51 | 5.35 | 4.85 | n/a | |
Par Pharmaceutical Companies, Inc
|
|
n/a | 930.602 | n/a | 31.98 | 1.83 | 1.40 | 2.68 | |
Savient Pharmaceuticals, Inc.
|
|
n/a | 641.745 | 10.64 | n/a | 13.51 | 17.98 | 3.61 | |
Indevus Pharmaceuticals
|
|
n/a | 407.437 | n/a | -8.95 | 7.46 | 6.19 | n/a | |
Paladin Labs Inc.
|
|
n/a | 157.472 | 31.29 | n/a | 3.76 | n/a | 3.46 | |
Common Sense Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
Shire plc (ADR)
|
|
n/a | 10,722.895 | 38.54 | 30.08 | 5.97 | 4.86 | 11.38 | |
Albany Molecular Research, Inc.
|
|
n/a | 314.068 | 143.99 | 32.03 | 1.75 | 1.63 | 1.12 | |
DepoMed, Inc.
|
|
n/a | 152.370 | n/a | -4.07 | 15.95 | 5.89 | n/a | |
University Of California, San Francisco
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 1,450.7 | 34.3 | 1,485.0 |
Other Revenue
|
144.2 | 0.0 | 144.2 |
| Total Revenue | 1,594.9 | 34.3 | 1,629.2 |
Cost of Revenue
|
581.2 | 0.0 | 581.2 |
SG&A Expense
|
450.2 | 49.0 | 499.2 |
Depreciation & Amortization
|
0.0 | 0.2 | 0.2 |
Research & Development
|
181.6 | 41.0 | 222.6 |
Interest Expense
|
0.0 | 0.0 | 0.0 |
Other Operating Expense
|
0.0 | 0.0 | 0.0 |
Unusual Expense (Income)
|
380.7 | 4.3 | 384.9 |
| Total Expenses | 1,593.7 | 94.4 | 1,688.1 |
Operating Income
|
1.2 | -60.0 | -58.8 |
| Non Operating Items | |||
Interest Expense (Inc.), Net Non-Oprtng
|
-7.0 | 3.6 | -3.4 |
Gain/Loss On Sale Of Assets
|
0.0 | -0.0 | -0.0 |
Other, Net
|
-55.1 | 0.0 | -55.1 |
| Income Before Taxes | -61.0 | -56.4 | -117.4 |
| Income Taxes | 119.5 | 0.3 | 119.8 |
| Income After Taxes | -180.4 | -56.7 | -237.1 |
| Minority Interest (IS) | 0.6 | 0.0 | 0.6 |
Net Income - Excl. Xord. Items
|
-179.8 | -56.7 | -236.5 |
| Accounting Change | 0.0 | -0.7 | -0.7 |
Net Income - Incl. Xord. Items
|
-179.8 | -57.4 | -237.2 |
Income Avail. to Common
|
-179.8 | -57.4 | -237.2 |
| Share Items | |||
Basic Avg. Shares Outstanding
|
106.4 | 37.0 | 143.4 |
Basic EPS - Excl. Xord. Items
|
n/a | n/a | -1.65 |
Basic EPS - Incl. Xord. Items
|
n/a | n/a | -1.65 |
| Full Dilution Adjustment | 0.0 | 0.0 | 0.0 |
| Fully Diluted Shares Outstanding | 106.4 | 37.0 | 143.4 |
F.D. EPS - Excl. Xord. Items
|
n/a | n/a | -1.65 |
F.D. EPS - Incl. Xord. Items
|
n/a | n/a | -1.65 |
| Balance Sheet | |||
| Assets | |||
Cash and Equivalents
|
232.0 | 87.0 | 319.0 |
ST Investments
|
673.8 | 60.0 | 733.8 |
Accounts Receivable
|
611.3 | 0.2 | 611.5 |
Inventory
|
452.4 | 0.0 | 452.4 |
Prepayments and Advances
|
36.0 | 1.1 | 37.1 |
Other Current Assets
|
82.6 | 0.0 | 82.6 |
Current Assets
|
2,088.0 | 148.3 | 2,236.3 |
PPE
|
1,207.0 | 2.9 | 1,209.9 |
Accum D&A
|
-196.8 | -0.7 | -197.5 |
PPE, Net
|
1,010.2 | 2.2 | 1,012.4 |
| Goodwill & Intangibles | 1,750.6 | 0.0 | 1,750.6 |
| Long Term Investments | 8.9 | 0.0 | 8.9 |
| Other Assets | 0.0 | 0.0 | 0.0 |
Other LT Assets
|
104.1 | 1.1 | 105.2 |
| Total Assets | 4,961.9 | 151.5 | 5,113.4 |
| Liabilities | |||
| Accounts Payable | 156.1 | 6.0 | 162.1 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 283.7 | 13.8 | 297.5 |
ST Debt
|
0.0 | 0.0 | 0.0 |
Curr Port of LTD & Cap Lease Oblg
|
742.4 | 137.8 | 880.2 |
| Other (Current) Liabilities | 29.6 | 9.6 | 39.2 |
Current Liab.
|
1,211.9 | 167.2 | 1,379.1 |
LT Debt
|
1,937.2 | 0.0 | 1,937.2 |
| Capitalized Lease Obligations | 0.0 | 0.0 | 0.0 |
Total LT Debt
|
1,937.2 | 0.0 | 1,937.2 |
| Minority Interest (BS) | 41.1 | 0.0 | 41.1 |
| Deferred Taxes | 221.9 | 0.0 | 221.9 |
Other LT Liab.
|
84.5 | 94.1 | 178.6 |
Total Liabilities
|
3,496.6 | 261.2 | 3,757.9 |
| Shareholders Equity | |||
| Common Stock | 1.1 | 0.0 | 1.1 |
| Additional Paid in Capital | 610.2 | 17.5 | 627.8 |
| Retained Earnings | 878.0 | -127.3 | 750.7 |
| Treasure Stock | -100.7 | 0.0 | -100.7 |
| Other Equity | 76.6 | 0.0 | 76.6 |
Total Equity
|
1,465.2 | -109.7 | 1,355.5 |
Total Liab. & Equity
|
4,961.9 | 151.5 | 5,113.4 |
Shares Outstanding
|
106.6 | 37.0 | 143.5 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | -179.8 | -57.4 | -237.2 |
| CF Depreciation | 110.9 | 0.2 | 111.1 |
| CF Deferred Taxes | -28.8 | 0.0 | -28.8 |
| Other Non-Cash Items | 456.5 | 42.7 | 499.2 |
| Change in Working Capital | 77.1 | 30.5 | 107.6 |
| Total Cash From Operating Activities | 435.9 | 15.9 | 451.8 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -58.6 | -2.1 | -60.7 |
| Other Investing Cash Flows | -2,612.1 | -10.8 | -2,622.8 |
| Total Cash From Investing Activities | -2,670.7 | -12.8 | -2,683.5 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | 0.0 | 0.0 | 0.0 |
| Purchase Or Sale of Stock | 36.0 | 31.7 | 67.7 |
| Purchase and Retirement of Debt | 2,409.9 | 89.7 | 2,499.6 |
| Other Financing Cash Flow | -8.6 | -41.0 | -49.6 |
| Total Cash From Financing Activities | 2,437.3 | 80.4 | 2,517.7 |
| Exchange Rate Effects | -0.6 | 0.0 | -0.6 |
| Net Change in Cash | 202.0 | 83.5 | 285.5 |
| Cash Taxes Paid | 104.4 | 0.0 | 104.4 |
| Cash Interest Paid | 6.5 | 0.0 | 6.5 |
Johnson & Johnson